NCT00216749已完成不适用
Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 650
- 试验地点
- 1
- 主要终点
- 1)Efficacy:Recurrence of cerebral infarction 2)Safety:Adverse Event
研究概览
简要总结
This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.
详细描述
This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction.
Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction.
- •Age: more than 18 years of age
排除标准
- •Unqualified patients judged by study investigator(s)
结局指标
主要结局
1)Efficacy:Recurrence of cerebral infarction 2)Safety:Adverse Event
时间窗: 3M
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pletaal SR Post Marketing Observational StudyIschemic SymptomsCerebral InfarctionNCT01782833Korea Otsuka Pharmaceutical Co., Ltd.3,635
终止
不适用
A Prospective, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral DefectsOsteochondral DefectsNCT01209390TiGenix n.v.8
进行中（未招募）
不适用
A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLSRestless Legs SyndromeNCT06076499Noctrix Health, Inc.325
已完成
不适用
A Post-marketing Observational Study of Cell Therapy for Chronic WoundsWoundsNCT01038986Macrocure Ltd.70
已完成
不适用
LifeVest Safety and Efficacy in Real Life Settings in FranceLeft Ventricular DysfunctionCardiac EventCardiac ArrythmiasSudden Cardiac DeathNCT03319160Zoll Medical Corporation1,164